Proteome Sciences (LON:PRM) Stock Price Down 15.2% – Time to Sell?

Proteome Sciences plc (LON:PRM) shares dropped 15.2% on Tuesday . The company traded as low as GBX 1.40 and last traded at GBX 1.40. 455,574 shares changed hands during mid-day trading, an increase of 10% from the average daily volume of 414,862 shares. The stock had previously closed at GBX 1.65.

Proteome Sciences Stock Performance

The firm has a market cap of £5.96 million, a P/E ratio of -1.63 and a beta of 0.15. The company has a current ratio of 0.13, a quick ratio of 0.37 and a debt-to-equity ratio of -165.46. The company’s 50-day moving average is GBX 1.60 and its two-hundred day moving average is GBX 1.87.

Proteome Sciences (LON:PRM) last issued its quarterly earnings data on Wednesday, April 15th. The company reported GBX (1.04) EPS for the quarter. Proteome Sciences had a positive return on equity of 33.80% and a negative net margin of 81.50%.The company had revenue of GBX 376 million for the quarter.

Proteome Sciences Company Profile

Proteome Sciences plc provides contract research services for the identification, validation, and application of protein biomarkers in the United States, the United Kingdom, European Union, and internationally. The company offers TMT LC-MS2, a standard method for analyzing cells and tissues when no phosphopeptide enrichment is required; TMT LC-MS3, a standard method for biomarker discovery in plasma and other samples where quantitative accuracy is a factor; SysQuant, provides an analysis of protein activity across regulatory and signaling pathways; and TMTcalibrator, analyzes where diseased or treated tissue can be analyzed in parallel with peripheral fluids.